Anavex life sciences and partex group announce strategic partnership to leverage ai for drug development and healthcare sales marketing building a patient-centric digital ecosystem

New york, june 27, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, and partex n.v. group (“partex”), the first data-to-drugs digital pharma platform, today announced a strategic partnership with the overall ambition to reshape the future of the biopharma business model.
AVXL Ratings Summary
AVXL Quant Ranking